Patents by Inventor Gershon Golomb
Gershon Golomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10722463Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: GrantFiled: March 6, 2018Date of Patent: July 28, 2020Assignee: Zuli Holdings Ltd.Inventors: Gershon Golomb, Hila Epstein, Eyal Afergan
-
Patent number: 10517883Abstract: A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intra-cellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages.Type: GrantFiled: June 27, 2003Date of Patent: December 31, 2019Assignee: ZULI HOLDINGS LTD.Inventors: Haim D. Danenberg, Gershon Golomb, Elazer R. Edelman
-
Publication number: 20190117678Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: ApplicationFiled: December 18, 2018Publication date: April 25, 2019Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG
-
Patent number: 10213446Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: October 24, 2017Date of Patent: February 26, 2019Assignee: BIOrest Ltd.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Publication number: 20180193265Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: ApplicationFiled: March 6, 2018Publication date: July 12, 2018Inventors: Gershon GOLOMB, Hila EPSTEIN, Eyal AFERGAN
-
Patent number: 9943481Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: GrantFiled: May 25, 2006Date of Patent: April 17, 2018Assignee: BIOrest Ltd.Inventors: Gershon Golomb, Hila Epstein, Eyal Afergan
-
Publication number: 20180064733Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.Type: ApplicationFiled: October 13, 2017Publication date: March 8, 2018Inventors: Yoram RICHTER, Gershon GOLOMB, Jonah B. SACHA
-
Publication number: 20180055860Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: ApplicationFiled: October 24, 2017Publication date: March 1, 2018Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG
-
Patent number: 9827254Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: October 27, 2016Date of Patent: November 28, 2017Assignee: BIOrest Ltd.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Patent number: 9820998Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.Type: GrantFiled: May 15, 2015Date of Patent: November 21, 2017Assignees: BIOREST LTD., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Yoram Richter, Gershon Golomb, Jonah B. Sacha
-
Publication number: 20170100415Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: ApplicationFiled: October 27, 2016Publication date: April 13, 2017Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG
-
Patent number: 9532956Abstract: The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component and a degradable component. As described herein, the particles and polymers may also include a hydrophilic component and/or a cleavable bond component. The particles and polymers described herein have been found to be particularly effective when used for delivery of one or more agents, such as one or more pharmaceutical agents. Other aspects of the invention are directed to methods of using or administering such particles or polymers, kits involving such particles or polymers, and the like.Type: GrantFiled: April 18, 2010Date of Patent: January 3, 2017Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital Inc.Inventors: Aleksandar Filip Radovic-Moreno, Weiwei Gao, Archana Swami, Gershon Golomb, Robert S. Langer, Omid C. Farokhzad
-
Patent number: 9498488Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: June 18, 2004Date of Patent: November 22, 2016Assignee: BIOrest LTD.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Publication number: 20150328237Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.Type: ApplicationFiled: May 15, 2015Publication date: November 19, 2015Inventors: Yoram RICHTER, Gershon GOLOMB, Jonah B. SACHA
-
Patent number: 8257742Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.Type: GrantFiled: February 16, 2006Date of Patent: September 4, 2012Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd.Inventors: Haim Danenberg, Morey Schachter, Gershon Golomb
-
Patent number: 8178128Abstract: A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.Type: GrantFiled: December 5, 2002Date of Patent: May 15, 2012Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Gershon Golomb, Haigt Sacks, Yousef Najareh, Elia Fishbein, Michael Chorny
-
Publication number: 20120021035Abstract: A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.Type: ApplicationFiled: July 16, 2010Publication date: January 26, 2012Inventors: Gershon Golomb, Haigt Sacks, Yousef Najareh, Elia Fishbein, Michael Chorny
-
Publication number: 20110065807Abstract: The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component and a degradable component. As described herein, the particles and polymers may also include a hydrophilic component and/or a cleavable bond component. The particles and polymers described herein have been found to be particularly effective when used for delivery of one or more agents, such as one or more pharmaceutical agents. Other aspects of the invention are directed to methods of using or administering such particles or polymers, kits involving such particles or polymers, and the like.Type: ApplicationFiled: April 18, 2010Publication date: March 17, 2011Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Aleksandar Filip Radovic-Moreno, Weiwei Gao, Archana Swami, Gershon Golomb, Robert S. Langer, Omid C. Farokhzad
-
Publication number: 20100015213Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: ApplicationFiled: May 25, 2006Publication date: January 21, 2010Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Gershon Golomb, Hila Epstein, Eyal Afergan
-
Publication number: 20090238876Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.Type: ApplicationFiled: February 16, 2006Publication date: September 24, 2009Inventors: Haim Danenberg, Morey Schachter, Gershon Golomb